[CHARGE syndrome in a neonate]

Bo Gao1, Shu Xiao1, Xiao-Wen Chen1

  • 1Center for Newborn Care, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.

Insights

A rare genetic disorder, CHARGE syndrome, was identified in an infant presenting with severe respiratory distress and distinctive facial features. Genetic testing revealed a CHD7 gene mutation, confirming the diagnosis and guiding critical care decisions.

Area of Science:

  • Genetics
  • Pediatrics
  • Rare Diseases

Background:

  • CHARGE syndrome is a complex genetic disorder with a wide spectrum of congenital anomalies.
  • Early diagnosis is crucial for appropriate management and genetic counseling.
  • Pierre Robin sequence can present with overlapping features, necessitating differential diagnosis.

Purpose of the Study:

  • To report a case of CHARGE syndrome diagnosed via whole-exome sequencing.
  • To highlight the role of the CHD7 gene in CHARGE syndrome.
  • To emphasize the importance of multidisciplinary care in managing this condition.

Main Methods:

  • Clinical presentation and diagnostic workup of an 11-day-old female infant.
  • Whole-exome sequencing to identify genetic mutations.
  • Multidisciplinary team approach for diagnosis and treatment planning.

Main Results:

  • The infant exhibited symptoms consistent with Pierre Robin syndrome, including dyspnea and dysmorphic facial features.
  • Whole-exome sequencing identified a heterozygous c.3082A>G mutation in the CHD7 gene, confirming CHARGE syndrome.
  • Despite supportive care, the infant's prognosis was poor, leading to treatment withdrawal.

Conclusions:

  • This case underscores the utility of genetic sequencing in diagnosing rare conditions like CHARGE syndrome.
  • CHD7 gene mutations are a significant cause of CHARGE syndrome.
  • Early identification and comprehensive management are vital for improving outcomes in infants with CHARGE syndrome.

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
308
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
159
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
170